JP Morgan Chase
BMY.RT

JP Morgan Chase’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

JP Morgan Chase’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,340,906
Closed -$3.69M – 6571
2020
Q4 		$3.69M Sell
5,340,906
-3,553,959
-40% -$7.57M ﹤0.01% 3046
2020
Q3 		$18M Sell
8,894,865
-2,485,026
-22% -$7.1M ﹤0.01% 1568
2020
Q2 		$40.7M Sell
11,379,891
-1,858,078
-14% -$6.7M 0.01% 989
2020
Q1 		$50.3M Sell
13,237,969
-9,945,960
-43% -$32.8M 0.01% 799
2019
Q4 		$69.8M Buy
+23,183,929
New +$60.3M 0.01% 801

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

JP Morgan Chase's BMY.RT Position: Q1 2021 in Review

JP Morgan Chase sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 5,340,906 shares — an estimated $3.69M sold.

JP Morgan Chase first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $69.8M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • JP Morgan Chase reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • JP Morgan Chase sold 5,340,906 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.69M.
  • JP Morgan Chase first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • JP Morgan Chase's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $69.8M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on JP Morgan Chase's 13F filing for Q1 2021, filed 12 May 2021.